The effect of lipoproteins on the development and progression of renal disease

American Journal of Nephrology
Lorien S Dalrymple, George A Kaysen

Abstract

The field of research examining how lipoproteins may contribute to the development and/or progression of renal disease has rapidly expanded over the last 25 years. In animal models, lipoproteins and lipids have been associated with both the initiation and progression of renal disease. Numerous potential mechanisms of lipoprotein-induced renal injury have been identified by utilizing animal models and tissue-culture experiments. However, with the exception of rare genetic mutations, the association between lipoproteins and human renal disease is less clear. In humans, the evidence that lipid-lowering therapy delays renal progression is limited. The purpose of this paper is to review the current literature on lipoprotein abnormalities and the development or progression of renal disease.

Citations

May 17, 2011·Histochemistry and Cell Biology·F BonominiR Rezzani
May 19, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Haiping YangQiu Li
May 22, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nosratola D VaziriBernardo Rodriguez-Iturbe
Oct 10, 2012·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Kyubok JinNosratola D Vaziri
Jun 23, 2012·Clinical and Experimental Nephrology·Kosaku Nitta
Jul 1, 2011·Current Medical Research and Opinion·Vassilios G AthyrosUNKNOWN Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group
Sep 25, 2012·Heart Failure Clinics·Jeong-a KimMichael J Quon
Nov 3, 2009·Biochimica Et Biophysica Acta·Kyu-hyang ChoNosratola D Vaziri
Sep 14, 2012·International Journal of Nephrology·Amy Rebecca BentleyCharles N Rotimi
Apr 30, 2015·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·P Y ZuoC Y Liu
Jan 7, 2018·Renal Failure·Shoko HonzumiItsuko Ishii
Apr 27, 2013·Journal of the American Society of Nephrology : JASN·Satoshi TakahashiYoshihisa Nojima
May 17, 2014·Clinical Journal of the American Society of Nephrology : CJASN·Mahboob RahmanUNKNOWN CRIC Study Investigators
May 8, 2009·American Journal of Physiology. Renal Physiology·Kyu-hyang ChoNosratola D Vaziri
Apr 6, 2011·Current Opinion in Lipidology·Vasilis Tsimihodimos, Moses Elisaf
Jan 20, 2011·Current Opinion in Nephrology and Hypertension·Sankar D NavaneethanGiovanni F M Strippoli
Feb 7, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·G ZoppiniM Muggeo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.